1. Barvaliya, M., Sanmukhani, J., Patel, T., Paliwal, N., Shah, H., Tripathi, C. Drug-induced Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS-TEN overlap: a multicentric retrospective study. J Postgrad Med. 2011;57(2):doi:10.4103/0022-3859.81865 21654132
Google Scholar | Medline2. Ferrandiz-Pulido, C., Garcia-Patos, V. A review of causes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Arch Dis Child. 2013;98(12):998-1003.doi:10.1136/archdischild-2013-303718 23873883
Google Scholar | Crossref | Medline3. Pavlos, R., Mallal, S., Phillips, E. HLA and pharmacogenetics of drug hypersensitivity. Pharmacogenomics. 2012;13(11):1285-1306.doi:10.2217/pgs.12.108 22920398
Google Scholar | Crossref | Medline4. Mockenhaupt, M . The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis. Expert Rev Clin Immunol. 2011;7(6):803-815.doi:10.1586/eci.11.66 22014021
Google Scholar | Crossref | Medline5. Yang, M-S., Lee, JY., Kim, J et al. Incidence of Stevens-Johnson syndrome and toxic epidermal necrolysis: a nationwide population-based study using National health insurance database in Korea. PLoS One. 2016;11(11):doi:10.1371/journal.pone.0165933 27835661
Google Scholar | Crossref | Medline6. Farhat, S., Banday, M., Hassan, I. Antecedent drug exposure aetiology and management protocols in Steven-Johnson syndrome and toxic epidermal necrolysis, a hospital based prospective study. J Clin Diagn Res. 2016;10(1):FC01.doi:10.7860/JCDR/2016/16430.7047 26894082
Google Scholar | Medline7. Harr, T., French, LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis. 2010;5(1):doi:10.1186/1750-1172-5-39 21162721
Google Scholar | Crossref | Medline8. French, LE . Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding. Allergol Int. 2006;55(1):9-16.doi:10.2332/allergolint.55.9 17075281
Google Scholar | Crossref | Medline9. Woolridge, KF., Boler, PL., Lee, BD. Tumor necrosis factor alpha inhibitors in the treatment of toxic epidermal necrolysis. Cutis. 2018;101(1):E15-21.29529123
Google Scholar | Medline10. Zhang, S., Tang, S., Li, S., Pan, Y., Ding, Y. Biologic TNF-alpha inhibitors in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a systemic review. J Dermatolog Treat. 2020;31(1):66-73.doi:10.1080/09546634.2019.1577548 30702955
Google Scholar | Crossref | Medline11. Wang, F., Ye, Y., Luo, Z-Y., Gao, Q., Luo, D-Q., Zhang, X. Diverse expression of TNF-α and CCL27 in serum and blister of Stevens-Johnson syndrome/toxic epidermal necrolysis. Clin Transl Allergy. 2018;8(1):doi:10.1186/s13601-018-0199-6 29713456
Google Scholar | Crossref | Medline12. Stern, RS., Divito, SJ. Stevens-Johnson syndrome and toxic epidermal necrolysis: associations, outcomes, and Pathobiology—Thirty years of progress but still much to be done. J Invest Dermatol. 2017;137(5):1004-1008.doi:10.1016/j.jid.2017.01.003
Google Scholar | Crossref | Medline13. Worswick, S., Cotliar, J. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of treatment options. Dermatol Ther. 2011;24(2):207-218.doi:10.1111/j.1529-8019.2011.01396.x 21410610
Google Scholar | Crossref | Medline14. Schneider, JA., Cohen, PR. Stevens-Johnson syndrome and toxic epidermal necrolysis: a concise review with a comprehensive summary of therapeutic interventions emphasizing supportive measures. Adv Ther. 2017;34(6):1235-1244.doi:10.1007/s12325-017-0530-y 28439852
Google Scholar | Crossref | Medline15. Moher, D, Liberati, A, Tetzlaff, J, Altman, DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):doi:10.1371/journal.pmed.1000097 19621072
Google Scholar | Crossref | Medline16. Gavigan, GM., Kanigsberg, ND., Ramien, ML. Pediatric Stevens-Johnson syndrome/toxic epidermal necrolysis halted by etanercept. J Cutan Med Surg. 2018;22(5):514-515.doi:10.1177/1203475418758989 29421925
Google Scholar | SAGE Journals | ISI17. Bastuji-Garin, S., Fouchard, N., Bertocchi, M., Roujeau, JC., Revuz, J., Wolkenstein, P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115(2):149-153.doi:10.1046/j.1523-1747.2000.00061.x 10951229
Google Scholar | Crossref | Medline | ISI18. Wells, GA., Shea, B., O’Connel, D et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute; 2011.
Google Scholar19. Higgins, JPT., Altman, DG., Gøtzsche, PC et al. The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:doi:10.1136/bmj.d5928 22008217
Google Scholar | Crossref | Medline20. Lee, Y-Y., Ko, J-H., Wei, C-H., Chung, W-H. Use of etanercept to treat toxic epidermal necrolysis in a human immunodeficiency virus-positive patient. Dermatologica Sinica. 2013;31(2):78-81.doi:10.1016/j.dsi.2012.06.005
Google Scholar | Crossref21. Paradisi, A., Abeni, D., Bergamo, F., Ricci, F., Didona, D., Didona, B. Etanercept therapy for toxic epidermal necrolysis. J Am Acad Dermatol. 2014;71(2):278-283.doi:10.1016/j.jaad.2014.04.044 24928706
Google Scholar | Crossref | Medline22. Chahal, D., Aleshin, M., Turegano, M., Chiu, M., Worswick, S. Vaccine-induced toxic epidermal necrolysis: a case and systematic review. Dermatol Online J. 2018;24(1):13030/qt7qn5268s 15 Jan 2018.doi:13030/qt7qn5268s 29469759
Google Scholar | Crossref | Medline23. Wang, C-W., Yang, L-Y., Chen, C-B et al. Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions. J Clin Invest. 2018;128(3):985-996.doi:10.1172/JCI93349 29400697
Google Scholar | Crossref | Medline24. Wallenborn, J., Fischer, M. Intensive care in a patient with toxic epidermal necrolysis. Case Rep Crit Care. 2017;2017:1-4.doi:10.1155/2017/3246196 29225976
Google Scholar | Crossref | Medline25. Worsnop, F., Wee, J., Natkunarajah, J., Moosa, Y., Marsden, R. Reaction to biological drugs: infliximab for the treatment of toxic epidermal necrolysis subsequently triggering erosive lichen planus. Clin Exp Dermatol. 2012;37(8):879-881.doi:10.1111/j.1365-2230.2012.04357.x 22548502
Google Scholar | Crossref | Medline26. Scott-Lang, V., Tidman, M., McKay, D. Toxic epidermal necrolysis in a child successfully treated with infliximab. Pediatr Dermatol. 2014;31(4):532-534.doi:10.1111/pde.12029 23072342
Google Scholar | Crossref | Medline27. Gubinelli, E., Canzona, F., Tonanzi, T., Raskovic, D., Didona, B. Toxic epidermal necrolysis successfully treated with etanercept. J Dermatol. 2009;36(3):150-153.doi:10.1111/j.1346-8138.2009.00616.x 19335689
Google Scholar | Crossref | Medline28. Patmanidis, K., Sidiras, A., Dolianitis, K et al. Combination of infliximab and high-dose intravenous immunoglobulin for toxic epidermal necrolysis: successful treatment of an elderly patient. Case Rep Dermatol Med. 2012;2012:1-3.doi:10.1155/2012/915314 23259092
Google Scholar | Medline29. Gaitanis, G., Spyridonos, P., Patmanidis, K et al. Treatment of toxic epidermal necrolysis with the combination of infliximab and high-dose intravenous immunoglobulin. Dermatology. 2012;224(2):134-139.doi:10.1159/000338202 22572593
Google Scholar | Crossref | Medline30. Paquet, P., Jennes, S., Rousseau, AF., Libon, F., Delvenne, P., Piérard, GE. Effect of N-acetylcysteine combined with infliximab on toxic epidermal necrolysis. A proof-of-concept study. Burns. 2014;40(8):1707-1712.doi:10.1016/j.burns.2014.01.027 24726294
Google Scholar | Crossref | Medline31. Chong, I., Chao, A. Stevens-Johnson syndrome/toxic epidermal necrolysis and treatment with a biologic: a case report. Perm J. 2017;21:doi:10.7812/TPP/16-060 28488978
Google Scholar | Medline32. Vivar, KL., Deschaine, M., Messina, J et al. Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy. J Cutan Pathol. 2017;44(4):381-384.doi:10.1111/cup.12876 28000240
Google Scholar | Crossref | Medline33. Famularo, G., Di Dona, B., Canzona, F., Girardelli, CR., Cruciani, G. Etanercept for toxic epidermal necrolysis. Ann Pharmacother. 2007;41(6):1083-1084.doi:10.1345/aph.1K001 17456541
Google Scholar | SAGE Journals | ISI34. Torres-Navarro, I., Briz-Redón, Álvaro., Botella-Casas, G et al. Accuracy of SCORTEN and ABCD-10 to predict mortality and the influence of renal function in Stevens-Johnson syndrome/toxic epidermal necrolysis. J Dermatol. 2020;47(10):1182-1186.doi:10.1111/1346-8138.15490 32856355
Google Scholar | Crossref | Medline35. Didona, D., Paolino, G., Garcovich, S., Caposiena Caro, RD., Didona, B. Successful use of etanercept in a case of toxic epidermal necrolysis induced by rituximab. J Eur Acad Dermatol Venereol. 2016;30(10):e83-e84.doi:10.1111/jdv.13330 26428058
Google Scholar | Crossref | Medline36. Wojtkiewicz, A., Wysocki, M., Fortuna, J., Chrupek, M., Matczuk, M., Koltan, A. Beneficial and rapid effect of infliximab on the course of toxic epidermal necrolysis. Acta Derm Venereol. 2008;88(4):420-421.doi:10.2340/00015555-0462 18709327
Google Scholar | Medline37. Zárate-Correa, LC., Carrillo-Gómez, DC., Ramírez-Escobar, AF., Serrano-Reyes, C. Toxic epidermal necrolysis successfully treated with infliximab. J Investig Allergol Clin Immunol. 2013;23(1):61-63.23653980
Google Scholar | Medline38. Hunger, RE., Hunziker, T., Buettiker, U., Braathen, LR., Yawalkar, N. Rapid resolution of toxic epidermal necrolysis with anti-TNF-alpha treatment. J Allergy Clin Immunol. 2005;116(4):923-924.doi:10.1016/j.jaci.2005.06.029 16210071
Google Scholar | Crossref | Medline39. Eliades, P., Fonseca, M., Harp, J. Use of etanercept in a series of pediatric patients with Stevens-Johnson Syndrome-Toxic epidermal necrolysis spectrum disease. JAMA Dermatol. 2020;156(8):921-922.doi:10.1001/jamadermatol.2019.3731 32347889
Google Scholar | Crossref | Medline40. Pham, CH., Gillenwater, TJ., Nagengast, E., McCullough, MC., Peng, DH., Garner, WL. Combination therapy: etanercept and intravenous immunoglobulin for the acute treatment of Stevens-Johnson syndrome/toxic epidermal necrolysis. Burns. 2019;45(7):1634-1638.doi:10.1016/j.burns.2018.12.018 31466921
Google Scholar | Crossref | Medline41. Shen, M-H., Liu, M-T., Chung, W-H., Lu, C-W. Toxic epidermal necrolysis induced by human herpesvirus 7 treated with a tumor necrosis factor-α inhibitor. J Dermatol. 2020;47(10):1179-1181.doi:10.1111/1346-8138.15493 32686137
Google Scholar | Crossref | Medline42. Wang, F., Gao, X., Chen, X., Tang, X., Chen, H., Han, J. Successful treatment of interstitial lung disease related to Stevens-Johnson syndrome/toxic epidermal necrolysis overlap with etanercept: a case report and published work review. J Dermatol. 2019;46(11):1035-1038.doi:10.1111/1346-8138.15058 31436331
Google Scholar | Crossref | Medline43. Wang, R., Zhong, S., Tu, P., Li, R., Wang, M. Rapid remission of Stevens-Johnson syndrome by combination therapy using etanercept and intravenous immunoglobulin and a review of the literature. Dermatol Ther. 2019;32(4):doi:10.1111/dth.12832 30659711
Google Scholar | Crossref | Medline44. López-Gómez, V., Yarza, R., Muñoz-González, H et al. Ribociclib-Related Stevens-Johnson syndrome: oncologic awareness, case report, and literature review. J Breast Cancer. 2019;22(4):661-666.doi:10.4048/jbc.2019.22.e44 31897340
Google Scholar | Crossref | Medline45. Coulombe, J., Belzile, E., Duhamel, A et al. Pediatric SJS/TEN subdued by a combination of dexamethasone, cyclosporine, and etanercept. J Cutan Med Surg. 2019;23(5):547-550.doi:10.1177/1203475419861078 31478770
Google Scholar | SAGE Journals | ISI46. Sibbald, C., Putterman, E., Micheletti, R., Treat, J., Castelo-Soccio, L. Retrospective review of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis cases at a pediatric tertiary care institution. Pediatr Dermatol. 2020;37(3):461-466.doi:10.1111/pde.14118 32058621